ClinicalTrials.gg
Not yet recruitingNCT07858825Updated Oct 5, 2026

Design and Pilot Implementation of a Chatbot to Support Breast Cancer Screening Among Black Women

An interventional study of Chatbot in Breast Cancer, sponsored by University of Washington. Not yet recruiting. Open to female participants aged 40 Years to 74 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by University of Washington · Not applicable, Interventional, and Health services research

How we know

Updated Oct 5, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
873
Allocation
Randomized
Ages
40 Years to 74 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 64 studies in Breast Neoplasms by University of Washington — 7 open to participants now, 11 under way, none of them phase 3. Breast Neoplasms · University of Washington.

Planned enrollment
Largest of 56
873 · median 35
Started
2026
with 2 others
No phase
15 of 64
1 open now
Primary completion
2027-03
later than 4 of 10 live
Registered
63rd of 64
by date

Among the 64 studies in Breast Neoplasms by University of Washington, this one has the largest planned enrollment of the 56 interventional ones that give a count, is one of 3 that started in 2026, is one of 15 with no phase, reaches primary completion later than 4 of the 10 other live ones, and was the 63rd registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

7 of the 64 studies in Breast Neoplasms by University of Washington are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 40 Years to 74 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Breast Neoplasms by University of Washington, or all of them as a file.
02

Study summary

Black women are more likely than White women to be diagnosed at later stages and to die from breast cancer. Increasing breast cancer screening rates could help improve early detection of and survival from breast cancer. To this end, this study seeks to implement and evaluate a culturally tailored chatbot intervention to increase breast cancer screening and address inequities among Black women using community-based research approaches.

We will conduct a pilot randomized quality improvement trial to test the efficacy of a chatbot outreach intervention, which provides breast cancer screening education and direct links to scheduling, on increasing breast cancer screening completion among Black women who receive primary care at the University of Washington (UW) Medicine. We hypothesize that compared to women who receive usual care, women who receive this novel chatbot outreach will have higher breast cancer screening completion rates at 90-days. In addition to quantitative assessment of chatbot effectiveness, we will also qualitatively evaluate chatbot acceptability, feasibility, and message relevance through interviews with a small group of participants about their experiences with the chatbot.

Read the detailed description

Our study purpose is to evaluate the effectiveness of a culturally tailored chatbot intervention to improve access to mammography scheduling and breast cancer screening (BCS) completion among average risk Black women who receive primary care at the University of Washington (UW) and are due for breast cancer screening.

This is a prospective, pilot randomized controlled trial that will evaluate the effectiveness of an outreach strategy in improving BCS completion via mammography. Individuals eligible for enrollment into the trial will be randomized to the two following interventions:

  1. Arm 1: Chatbot intervention: SMS/text message with breast cancer screening educational and scheduling information; reminder message at 2-weeks.
  2. Arm 2: Control: usual care.

Random assignments will be based on a randomization scheme called Big Stick Design with a maximum tolerated imbalance between groups of 4. This design allows random assignments to be generated in a way that limits the imbalance between arms within strata, while ensuring that the sequence is not predictable based on previous assignments. Randomization will be stratified within arms by 1) age (40-55 years vs. 56-74 years - to account for potential differences in recommendations for mammogram frequency and comfort with technology/chatbots), 2) history of any prior breast cancer screening (prior screener vs. never screener), 3) campaign messaging status (received UW Medicine Population Health breast cancer screening campaign outreach message in August 2026 vs. did not receive outreach message in August 2026).

We plan to stagger the timing of chatbot outreach based on mammogram access in coordination with the UW radiology department. For example, if there are 20 slots available in the next 2 weeks across sites, we may send chatbot outreach to 100 eligible participants (with expected \~20% response rate to successful outreach interventions among people overdue for screening). If there is a delay between randomization and intervention group chatbot outreach (i.e. due to staggering), we will confirm if participants have scheduled mammography in interim and are therefore no longer eligible for study participation before intervention outreach messaging is sent.

Our primary outcome of interest is proportion of participants who completed BCS at 90 days following initial chatbot outreach. Our secondary outcome of interest is proportion of participants who scheduled or completed BCS at 90 days following initial chatbot outreach (i.e. measuring implementation effectiveness). We will also perform a sensitivity analysis measuring both primary and secondary outcomes at 180 days following initial chatbot outreach (i.e. to account for delays in scheduling/outreach).

We will perform intention-to-treat (ITT) analyses. First, we will use the Pearson's chi-square test of homogeneity to assess for statistically significant differences between randomization group and control group mammogram completion rate at 90 days post chatbot outreach (primary outcome), or mammogram scheduling/completion rate at 90 days post chatbot outreach (secondary outcome). We will then conduct a multivariable logistic regression analysis to test the association between randomization group and mammogram completion at 90 days post chatbot outreach (primary outcome), or mammogram scheduling/completion at 90 days post chatbot outreach (secondary outcome), adjusting for individual- (e.g., age, insurance status, patient portal use, primary care visits in last year, previous BCS), clinic- (e.g., clinic group), and system-level characteristics (e.g. campaigns messaging), including stratification factors, to address covariate imbalance between groups and improve precision in the analysis. We will estimate adjusted risk differences from these models using predictive margins.

Finally, we will conduct unadjusted exploratory subgroup analyses. We will explore intervention effect consistency between: 1) participants who use the patient portal and those who do not use the patient portal; 2) participants who receive primary care through a university hospital-based clinic, county hospital-based clinic, or community-based clinic; 3) among intervention group participants who responded to text messages and/or reached scheduling message (i.e. interacted with chatbot) vs. those who did not.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • chatbot
  • breast cancer screening
  • mammogram
  • text message
04

Who can participate

Ages eligible
40 Years to 74 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 40 through 74 years at the time of eligibility assessment.
  • Assigned female at birth.
  • An active UW Medicine primary-care patient and included in the UW Medicine population-health breast cancer screening outreach population.
  • Due for breast cancer screening, defined as having no documented mammogram within the prior 24 months, based on the UW Medicine adaptation of the NCQA HEDIS breast cancer screening measure.
  • Have a mobile phone number on file and opted in to receiving text messages from UW Medicine.
  • Eligible to receive routine breast cancer screening outreach according to UW Medicine clinical and operational criteria.

Exclusion criteria

Exclusion Criteria:

  • History of bilateral mastectomy.
  • EHR diagnosis or indicator of palliative care, advanced illness, or frailty.
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
873 participants (estimated)

Study arms

  • No intervention
    Usual care

    Patients in this arm may receive breast cancer screening counseling and/or mammogram referral through usual primary care. This could include during primary care visit, patient portal message, phone call or letter.

  • Experimental
    Chatbot intervention

    Initial chatbot outreach with education and direct mammogram scheduling capability, with one conditional follow-up message at approximately Day 14

    Other: Chatbot

Interventions

  • OtherChatbot

    Chatbot-based outreach that provides breast cancer screening education, allows participants to learn more about screening, and offers direct mammography scheduling through the chatbot

06

What researchers measure

Primary outcomes

  1. Proportion of participants completing BCS 90 days after initial outreach

    Time frame: 90-days

Secondary outcomes

  1. Proportion of participants who schedule or complete BCS 90 days after initial outreach

    Time frame: 90-days

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Marcotte LM, Deeds S, Wheat C, Gunnink E, Gray K, Rojas J, Finch C, Nelson K, Reddy A. Automated Opt-Out vs Opt-In Patient Outreach Strategies for Breast Cancer Screening: A Randomized Clinical Trial. JAMA Intern Med. 2023 Nov 1;183(11):1187-1194. doi: 10.1001/jamainternmed.2023.4321. PubMed 37695621 ↗
  • Marcotte LM, Khor S, Wong ES, Akinsoto N, Lee ES, Onstad S, Issaka RB. A Pilot Analysis of Patient Portal Use and Breast Cancer Screening Among Black Patients in a Large Academic Health System. AJPM Focus. 2024 Nov 22;4(1):100305. doi: 10.1016/j.focus.2024.100305. eCollection 2025 Feb. PubMed 39866156 ↗
  • Marcotte LM, Langevin R, Hempstead BH, Ganguly A, Lyon AR, Weiner BJ, Akinsoto N, Houston PL, Fang V, Hsieh G. Leveraging human-centered design and causal pathway diagramming toward enhanced specification and development of innovative implementation strategies: a case example of an outreach tool to address racial inequities in breast cancer screening. Implement Sci Commun. 2024 Mar 28;5(1):31. doi: 10.1186/s43058-024-00569-w. PubMed 38549174 ↗
  • Marcotte LM, Khor S, Reddy A, Morenz A, Nelson K, Akinsoto N, Lee ES, Onstad S, Wong ES. An analysis of multilevel factor contributions to breast cancer screening inequities in an academic health system. Cancer. 2025 Feb 1;131(3):e35734. doi: 10.1002/cncr.35734. PubMed 39865423 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Mar 2027, 4 months later.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 4 months is below that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2026
First posted
Oct 5, 2026
StartEst.
Oct 26, 2026
Primary completionEst.
Mar 1, 2027
CompletionEst.
Jun 1, 2027
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07858825
Collaborators
Novartis Pharmaceuticals, National Comprehensive Cancer Network
Responsible party
Leah Marcotte (Assistant Professor: School of Medicine, General Internal Medicine, University of Washington) — Principal investigator
First posted
Oct 5, 2026
Start date
Oct 26, 2026 (estimated)
Primary completion
Mar 1, 2027 (estimated)
Completion
Jun 1, 2027 (estimated)
Last update
Oct 5, 2026

Study contacts

Leah Marcotte, MD, MS
Contact
leahmar@uw.edu
206-598-8750
Olivia Gregorich, MS
Contact
olivia02@uw.edu
Leah Marcotte, MD, MS
principal investigator · University of Washington

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion